Niijima, T <br/><br/>
[Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors].  [electronic resource] 

 -  Hinyokika kiyo. Acta urologica Japonica  Oct 1992 
 - 1201-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0018-1994 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anorexia--etiology<br/>Carcinoma, Renal Cell--therapy<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Fever--etiology<br/>Humans<br/>Infusions, Intravenous<br/>Injections, Intramuscular<br/>Interferon-alpha--administration & dosage<br/>Kidney Neoplasms--therapy<br/>Leukopenia--etiology<br/>Male<br/>Middle Aged<br/>Tumor Necrosis Factor-alpha--administration & dosage